Breckenridge Pharmaceutical, Inc. announced the immediate launch of Methylergonovine Maleate Injection, USP 0.2mg/mL. This product is an AP rated generic to Methergine®, a product owned by Edison Therapeutics, LLC. and is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.
GE Healthcare’s Life Sciences business and Valneva SE, a fully integrated vaccine biotech company, are sharing the results of a successful collaboration to optimize virus productivity in Valneva’s EB66® cell-line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health vaccines.
Law enforcement agents, narcotics officers and customs personnel can now quickly and safely detect street drug W-18 and other lethal drugs with the newest library update for the Thermo Scientific TruNarc handheld narcotics analyzer. W-18 is a new designer drug considered to be significantly more potent than morphine and fentanyl.
Daiichi Sankyo Company, Limited announced that it has entered into a strategic collaboration with AgonOx, Inc., a privately held biotechnology company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer, to develop an undisclosed immuno-oncology target.
Janssen Biotech Inc announced that the U.S. FDA has approved STELARA® (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers.